- Home
- BIIB vs BCE Comparison
BIIB vs BCE Comparison
Compare BIIB & BCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- BCE
- Stock Information
- Founded
- BIIB 1978
- BCE 1880
- Country
- BIIB United States
- BCE Canada
- Employees
- BIIB N/A
- BCE N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- BCE
- Sector
- BIIB Health Care
- BCE
- Exchange
- BIIB Nasdaq
- BCE Nasdaq
- Market Cap
- BIIB 18.8B
- BCE 20.2B
- IPO Year
- BIIB 1991
- BCE N/A
- Fundamental
- Price
- BIIB $124.99
- BCE $23.69
- Analyst Decision
- BIIB Buy
- BCE Hold
- Analyst Count
- BIIB 27
- BCE 6
- Target Price
- BIIB $188.17
- BCE $37.50
- AVG Volume (30 Days)
- BIIB 1.2M
- BCE 3.5M
- Earning Date
- BIIB 07-31-2025
- BCE 08-07-2025
- Dividend Yield
- BIIB N/A
- BCE 10.33%
- EPS Growth
- BIIB 26.39
- BCE N/A
- EPS
- BIIB 10.12
- BCE 0.30
- Revenue
- BIIB $9,816,400,000.00
- BCE $16,925,592,229.00
- Revenue This Year
- BIIB N/A
- BCE $0.33
- Revenue Next Year
- BIIB N/A
- BCE $2.23
- P/E Ratio
- BIIB $12.35
- BCE $80.18
- Revenue Growth
- BIIB 1.59
- BCE N/A
- 52 Week Low
- BIIB $110.04
- BCE $20.28
- 52 Week High
- BIIB $236.48
- BCE $36.17
- Technical
- Relative Strength Index (RSI)
- BIIB 41.14
- BCE 58.96
- Support Level
- BIIB $132.37
- BCE $23.64
- Resistance Level
- BIIB $137.84
- BCE $24.60
- Average True Range (ATR)
- BIIB 4.16
- BCE 0.54
- MACD
- BIIB -0.68
- BCE 0.07
- Stochastic Oscillator
- BIIB 7.82
- BCE 68.12
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About BCE BCE Inc.
BCE provides wireless, broadband, television, and landline phone services in Canada. It is one of the Big Three national wireless carriers, with over 10 million customers constituting about 30% of the market. It is also the incumbent local exchange carrier—the legacy telephone provider—throughout much of the eastern half of Canada, including in the most populous Canadian provinces: Ontario and Quebec. BCE has a media segment that holds television, radio, and digital media assets. BCE licenses the Canadian rights to movie channels including HBO, Showtime, and Starz.